StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

Investment analysts at StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report released on Saturday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Trading Down 0.6 %

Shares of NYSE:BTX opened at $6.54 on Friday. The stock has a fifty day simple moving average of $3.25 and a two-hundred day simple moving average of $1.69. Brooklyn ImmunoTherapeutics has a 12-month low of $6.35 and a 12-month high of $8.31. The stock has a market capitalization of $384.72 million, a price-to-earnings ratio of -2.88 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.